Cargando…

Rituximab for treatment of severe lupus nephritis

Detalles Bibliográficos
Autores principales:	Baskin, E, Bayrakci, US, Ozen, S, Bilginer, Y, Gulleroglu, KS, Ozdemir, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334055/ http://dx.doi.org/10.1186/1546-0096-6-S1-P249

Ejemplares similares

The association of Familial Mediterranean Fever and cryptogenic cirrhosis
por: Baskin, E, et al.
Publicado: (2008)

PReS-FINAL-2087: Diagnosis of arthritis: history or laboratory?
por: Yurtsever, O, et al.
Publicado: (2013)

PReS-FINAL-2214: Validation of new pediatric criteria in diagnosis of Familial Mediterranean Fever in children
por: Baskin, E, et al.
Publicado: (2013)

Rituximab is effective in the treatment of nephritis in lupus patients, refractory to conventional immunosuppressive therapy
por: Martínez, R, et al.
Publicado: (2010)

Peripheric arterial aneurisyms and monocytosis in intravenous immunoglobulin treatment resistant Kawasaki disease
por: Baskin, E, et al.
Publicado: (2008)

PReS-FINAL-2262: Arthritis in a patient with type 1 glycogen storage disease
por: Baskin, E, et al.
Publicado: (2013)

PReS-FINAL-2310: Successful rituximab treatment in a 14 year-old boy with lupus nephritis
por: Torrente-Segarra, V, et al.
Publicado: (2013)

Safety and efficacy of rituximab in refractory pediatric Systemic Lupus Erythematosus nephritis: a single-center experience of northern Greece
por: Trachana, M, et al.
Publicado: (2011)

Hematological features in children with systemic lupus erythematosus: are they more common than appreciated?
por: Gokce, Muge, et al.
Publicado: (2011)

Effective use of rituximab in combination with low dose cyclophosphamide in childhood onset systemic lupus erythematosus (SLE) with relapsing class IV nephritis
por: Miettunen, PM, et al.
Publicado: (2008)

Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
por: Mina, Rina, et al.
Publicado: (2012)

Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014)

Behcet Disease: treatment of vascular involvement in children
por: Bilginer, Y, et al.
Publicado: (2008)

The role of antimalarials in lupus nephritis: a review
por: Lee, Senq-J, et al.
Publicado: (2012)

Anakinra for secondary amyloidosis in an adolescent with FMF and Behcet Disease
por: Bilginer, Y, et al.
Publicado: (2008)

PReS-FINAL-2218: Treatment of colchicines resistant FMF: experience of a pediatric center in Turkey
por: Kara Eroglu, F, et al.
Publicado: (2013)

MicroRNA's role as biomarkers of lupus nephritis in children
por: Abulaban, Khalid, et al.
Publicado: (2014)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Use of mycophenolate mofetil (MMF) in lupus nephritis (LN) in children
por: Indaco, R, et al.
Publicado: (2008)

The effect of juvenile systemic lupus erythematosus serum activated macrophages on a lupus nephritis model
por: Vernon, April S, et al.
Publicado: (2014)

Clinical efficacy and safety of rituximab in lupus nephritis
por: Zhong, Zhiqing, et al.
Publicado: (2019)

Acute phase reactants in the follow-up of patients with FMF
por: Arıcı, ZS, et al.
Publicado: (2015)

Pediatric lupus nephritis: impact of ethnicity on histological subtype and initial presentation
por: Jurencak, R, et al.
Publicado: (2008)

Urinary VCAM-1 as a biomarker of lupus nephritis disease activity
por: Smith, Eve, et al.
Publicado: (2014)

Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Profile of cytokines, growth factors and chemokines during attacks of FMF
por: Bilginer, Y, et al.
Publicado: (2008)

PReS-FINAL-2279: Lupus nephritis in a Colombian cohort of pediatric patients
por: Diaz Maldonado, AS, et al.
Publicado: (2013)

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis
por: Suh, Chang-Hee
Publicado: (2022)

The effect of Rituximab treatment on T cells
por: Diaz-Torné, C, et al.
Publicado: (2010)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

PReS-FINAL-2299: Novel biomarkers for the assessment of pediatric systemic lupus erythematosus nephritis (preliminary report)
por: Koutsonikoli, A, et al.
Publicado: (2013)

New aspects of the etiopathogenesis of systemic lupus erythematosus
por: Gaipl, US, et al.
Publicado: (2003)

A safe protocol for tuberculin test assessment in a country where BCG vaccination is mandatory
por: Ayaz, N Aktay, et al.
Publicado: (2008)

PReS-FINAL-2354: Laboratory investigation of the role of toll-like receptros on kidney cells in pathogenesis of lupus nephritis
por: Sen, E, et al.
Publicado: (2013)

Treatment of calcinosis with biphosphonates in juvenile dermatomyositis
por: Bilginer, Y, et al.
Publicado: (2008)

Dramatic Response of Lupus Enteritis, Nephritis, and Pancytopenia to Plasmapheresis and Rituximab
por: Aftab, Adan, et al.
Publicado: (2022)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Does unity of Familial Mediterranean fever with juvenile idiopathic arthritis affect the outcome?
por: Topaloglu, R, et al.
Publicado: (2008)

The role of clinical pilates exercises in children wıth juvenile idiopathic arthritis: a pilot study
por: Unal, Edibe, et al.
Publicado: (2011)

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
por: Eisenberg, RA, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_oakn2ht7kihk09hl6qgc7kqegh